N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as GPR17 modulators for treating CNS disorders such as multiple sclerosis

US12358875B2 · kind B2 · utility

Assignee

• UCB Pharma GMBH · DE

Inventors

• Cecile Pegurier · Uccle - Ukkel, BE
• Silvia Lovera · Brussels, BE
• Christa E. Mueller · Bonn, DE
• Joerg Hockemeyer · Bonn, DE
• Mahmoud Rashed · Bonn, DE
• Ali El-Tayeb · Bonn, DE
• Yong Zhang · Princeton, US

Key dates

• Filing date: Jun 16, 2020
• Grant date: Jul 15, 2025
• Expiry date: Jun 1, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Disclosed are N-(phenyl)-1H-indole-3-sulfonanmide and N-(phenyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide derivatives of formula I substituted at the 1- and 6-positions of the 1H-indole or 1H-pyrrolo[2,3-b]pyridine moiety, as well as structurally related compounds (e.g. the N-pyridin-2-yl and the N-pyridin-3-yl analogues thereof). The present compounds have GPR17 modulating properties which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating disorders such as multiple sclerosis.